Genetics
Biotechnology company Biogen (Cambridge, MA) recently committed $20 million into a collaboration with the University of Pennsylvania to co-develop gene therapies using next-generation adeno-associated virus…
Read More
The Transcend acquisition tops the list, but February was a promising month for ophthalmology. Alcon Leaps into MIGS with Transcend With its acquisition of Transcend…
Read More
How far will Avalanche Biotechnologies Inc.’s pivot take it outside of ophthalmology? Following the release of disappointing topline results of its lead gene therapy candidate…
Read MorePositive top-line results from a pivotal Phase III study may result in the first gene therapy to win U.S. regulatory approval, and sent shares of…
Read More- « Previous
- 1
- 2
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")